Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Accumulated Expenses (2020 - 2025)

Foghorn Therapeutics has reported Other Accumulated Expenses over the past 6 years, most recently at $400000.0 for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $400000.0 for Q4 2025, up 39900.0% from a year ago — trailing twelve months through Dec 2025 was $400000.0 (up 39900.0% YoY), and the annual figure for FY2025 was $400000.0, up 39900.0%.
  • Other Accumulated Expenses for Q4 2025 was $400000.0 at Foghorn Therapeutics, up from $396000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for FHTX hit a ceiling of $526000.0 in Q1 2025 and a floor of $1000.0 in Q4 2024.
  • Median Other Accumulated Expenses over the past 5 years was $272000.0 (2022), compared with a mean of $257470.6.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 97.22% in 2024 and later soared 39900.0% in 2025.
  • Foghorn Therapeutics' Other Accumulated Expenses stood at $392000.0 in 2021, then dropped by 18.88% to $318000.0 in 2022, then tumbled by 88.68% to $36000.0 in 2023, then tumbled by 97.22% to $1000.0 in 2024, then soared by 39900.0% to $400000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $400000.0 (Q4 2025), $396000.0 (Q3 2025), and $392000.0 (Q2 2025) per Business Quant data.